Intelligence Platform

Patents

Browse 29,054 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11965161

Methods and compositions for sensitization of tumor cells to immune therapy

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11965040

Modulation of complement activity

RA PHARMACEUTICALS, INC. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11963945

Ozonides for treating or preventing virus infections

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11965166

Complement factor B (CFB) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11965190

Vectors, genetically modified bacteria, and methods of making and using

Regents of the University of Minnesota · Granted Tue Apr 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957677

Cancer treatment using FGFR inhibitors and PLK1 inhibitors

Cardiff Oncology, Inc. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957680

Pyruvate kinase activators for use in treating blood disorders

Agios Pharmaceuticals, Inc. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957675

Methods and uses for treating anhedonia

Xenon Pharmaceuticals Inc. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957740

Complex of botulinum neurotoxin E and its binding protein as a formulation with enhanced p

Prime Bio, Inc. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957686

Compositions for delivery of reboxetine

AXSOME THERAPEUTICS, INC. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957683

Bicyclic compounds

Aligos Therapeutics, Inc. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11959096

Methods for selective inhibition of pluripotent stem cells

The Government of the United States of America as Represented by the Secretary of the Department of Health and Human Services NIH, Office of Technology Transfer · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11959081

Transthyretin (TTR) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11959082

Dual activity super toxic RNAi active dsRNAs

Northwestern University · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11959084

Nucleic acid construct

AUTOLUS LIMITED · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957704

Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit be

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11959080

Methods and compositions for inhibiting PMP22 expression

Ionis Pharmaceuticals, Inc. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957674

Formulations of a somatostatin modulator

CRINETICS PHARMACEUTICALS, INC. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957655

Methods of treating hearing loss

The Regents of the University of California · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957684

Treatment of heavy menstrual bleeding associated with uterine fibroids

Takeda Pharmaceutical Company Limited · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11958879

Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof

Enanta Pharmaceuticals, Inc. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11958862

Compounds and compositions and uses thereof

PGI Drug Discovery LLC · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957687

Modulators of HSD17B13 and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11957754

Clinical formulations

Astellas Institute for Regenerative Medicine · Granted Tue Apr 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted